Healix

Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers

Quyen Luu – Central Georgia Infectious Diseases, Macon, GA
H. Barry Baker – Infectious Disease Physicians, Miami, FL
Ramesh V. Nathan – Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
Richard L. Hengel – Atlanta ID Group, Atlanta, GA
Alfred E. Bacon, III – Infectious Disease Associates, PA, Newark, DE
Richard C. Prokesch – Infectious Diseases Associates, Riverdale, GA
Carson T. Lo – West Houston Infectious Disease Associates, Houston, TX
Kimberly A. Couch – Healix Infusion Therapy, Sugar Land, TX
Claudia P. Schroeder – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen – Healix Infusion Therapy, Sugar Land, TX

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound